CCSD code 0048F: Potassium blood test billing guide for UK practitioners
CCSD Code 0048F is the UK private medical insurance code for a potassium blood test. It covers a routine pathology investigation, billed thousands of times a day across UK private practices, that measures the concentration of potassium in a blood sample. Practice management software like Pabau helps UK private practices get these claims right the […]
CCSD code 0043G: Iron regulatory gene panel
CCSD code 0043G is the iron regulatory gene panel, a pathology test within the industry-standard procedure schedule used by every major UK private medical insurer, including Bupa, AXA Health, Aviva, Vitality Health, and Allianz Care. Most claim rejections aren’t caused by the wrong code. They’re caused by incomplete documentation, a mismatched diagnostic code, or a […]
CCSD Code XR580: Percutaneous Cholecystostomy Billing Guide
Private radiology and diagnostic services account for a significant share of UK private healthcare invoicing. Getting the code right on the first submission is the difference between prompt reimbursement and a protracted back-and-forth with an insurer’s billing team. CCSD Code XR580 covers a specific diagnostic imaging or radiology procedure billable to private medical insurers under […]
CCSD Code X6015: High dose brachytherapy preparation
Most billing teams working in UK private oncology know that brachytherapy planning is clinically intensive. What trips them up is the coding: specifically, whether the planning and preparation phase for high dose brachytherapy has its own dedicated CCSD procedure code, or whether it needs to be bundled with the treatment delivery code. The answer matters […]
CCSD code 0051G: Urine guanidinoacetate (GUAN) billing guide
CCSD code 0051G bills the laboratory measurement of urine guanidinoacetate (GUAN), a test ordered when a patient is being investigated for a suspected disorder of creatine synthesis or transport. The code sits within the diagnostic schedule maintained by the Clinical Coding and Schedule Development (CCSD) Group, covered in more depth on Pabau’s diagnostic codes hub, […]
CCSD code 0264F: Laxative screen billing guide
CCSD code 0264F: What it is and how to bill it correctly CCSD code 0264F is the Laxative Screen, a pathology procedure classified under Chapter 34 (Pathology), subsection 34.1.1, “CCSD Schedule – Codes,” within the CCSD Schedule, the industry-standard coding system for UK private healthcare. Getting the code right the first time means faster reimbursement […]
CCSD code 0430B: RI immunoglobulin G antibody billing guide
CCSD code 0430B is the diagnostic pathology code UK private insurers use to bill the RI immunoglobulin G (IgG) antibody test, part of the Immunology specialty, Chapter 34, in the CCSD Schedule of Diagnostic Tests. Automating the coding and submission workflow — the kind of features that save private practices time — only helps once […]
CCSD code 0028G: Clinical description, billing and insurer guide
CCSD code 0028G is a diagnostic code from the Clinical Coding and Schedule Development (CCSD) Group’s schedule, used by UK private healthcare providers to bill insurers for a Single Gene Test of the SRD5A2 gene. Getting this code right on an invoice is not a formality. It is the single factor that determines whether a […]
CCSD code 0035G: CD279 (PD-1) mutation analysis billing guide
Most billing errors on CCSD Code 0035G come from a single mix-up: treating a blood-based genetic test like a surgical or clinical procedure. CD279 (PD-1) mutation analysis is a molecular pathology test run on a blood sample, and how you classify it in your billing system determines whether the claim pays or bounces. For practices […]
CCSD code 0019G: EGFR vIII mutation test billing guide
CCSD code 0019G is the UK private healthcare billing code for the EGFR vIII mutation test, a molecular pathology analysis that looks for the epidermal growth factor receptor variant III (EGFRvIII) mutation in a submitted tumor tissue sample. Clinicians order it mainly during the diagnostic workup of glioblastoma and other high-grade gliomas, where EGFRvIII status […]